Why All Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Should Have Their Tumors Tested for EGFR and ALK Abnormalities

The anaplastic lymphoma kinase (ALK) fusion oncogene and the epidermal growth factor receptor (EGFR) represent molecular targets in a subset of non-small cell lung cancers (NSCLCs). NSCLC accounts for nearly 85 % of all lung cancers with 7 % of… [Learn More…]

Resveratrol (SRT501) Increases Apoptosis of Liver Metastasis in Patients with Colorectal Cancer

SRT501 is a micronized formulation of resveratrol that has significantly increased oral bioavailability. In this study, patients with colorectal cancer and hepatic metastases scheduled to undergo hepatectomy were given SRT501 prior to surgery…. [Learn More…]

Concurrent Chemo-Radiation During Primary Treatment Reduces Recurrence Due to Micro-Metastasis

It is well accepted that micro-metastasis of the primary tumor is responsible for disease recurrence and metastasis. However, by the time most primary tumors are detected using standard diagnostic assays, distant micro-metastasis has likely occurred… [Learn More…]

Advanced Stem Cell Transplants for Blood Cancer Patients

For patients suffering from blood cancers, a stem cell transplant can be a life saving procedure. With allogeneic stem cell transplants, the stem cells are taken from a matched donor (typically a family member) and infused into an immune suppressed… [Learn More…]

Determining Time to First Treatment for Patients With Chronic Lymphocytic Leukemia (CLL)

The time to progression for CLL can vary greatly between patients with some patients never needing treatment and others with aggressive disease requiring early treatment. For newly diagnosed patients, the uncertainty of the current “wait-and-see… [Learn More…]

Cetuximab and Chemoradiation Therapy Significantly Improves Overall Survival of Patients with Unresectable Stage III NSCLC

Non-small cell lung cancers (NSCLC) commonly express the epidermal growth factor receptor (EGFR), which is associated with poor clinical outcome. Cetuximab is an inhibitor of EGFR and has radio-sensitization properties. In this study of patients… [Learn More…]

JX-594 Update: Improved Survival for Patients with Advanced Hepatocellular Carcinoma

In this phase II trial of patients with advanced, previously treated hepatocellular carcinoma (HCC),  52% of patients exhibited disease stabilization. The median overall survival was  13.8 mths with 25% of patients survived 32 mths (to date)…. [Learn More…]

Vandetanib for Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)

Medullary thyroid cancer (MTC) can usually be treated with surgery. However, treatment options for patients with unresectable, recurrent or metastatic MTC are limited. Mutations in the RET gene are common in sporadic MTC with the most common… [Learn More…]

Exemestane Offers New Option for Breast-Cancer Prevention

Exemestane is an aromatase inhibitor that substantially reduces the risk of invasive breast cancer in postmenopausal women at high risk of developing the disease. A 3yr follow up found that patients who took exemestane were 65% less likely to… [Learn More…]

Cabozantinib for Castration-Resistant Prostate Cancer

Cabozantinib is a multiple tyrosine kinase inhibitor that blocks the vascular endothelial growth factor receptor (VEGFR) and the receptor of hepatocyte growth factor (C-MET), resulting in significant benefits for patients with metastatic prostate… [Learn More…]